Arrowstreet Capital Limited Partnership Has $191.40 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Arrowstreet Capital Limited Partnership reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 542,445 shares of the biotechnology company's stock after selling 99,154 shares during the quarter. Arrowstreet Capital Limited Partnership owned 1.21% of United Therapeutics worth $191,396,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of UTHR. Allstate Corp acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $415,000. Orion Portfolio Solutions LLC increased its stake in United Therapeutics by 22.4% in the 4th quarter. Orion Portfolio Solutions LLC now owns 4,021 shares of the biotechnology company's stock valued at $1,419,000 after buying an additional 735 shares during the period. denkapparat Operations GmbH acquired a new position in United Therapeutics in the 4th quarter valued at approximately $394,000. Pictet Asset Management Holding SA lifted its position in United Therapeutics by 142.6% in the 4th quarter. Pictet Asset Management Holding SA now owns 118,091 shares of the biotechnology company's stock worth $41,667,000 after buying an additional 69,411 shares in the last quarter. Finally, New Age Alpha Advisors LLC acquired a new stake in shares of United Therapeutics during the 4th quarter valued at $1,636,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $929,678.52. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,500 shares of company stock worth $26,134,500. Company insiders own 11.90% of the company's stock.

Remove Ads

United Therapeutics Stock Down 2.1 %

UTHR stock traded down $6.39 during midday trading on Friday, hitting $300.98. 104,859 shares of the company traded hands, compared to its average volume of 449,050. United Therapeutics Co. has a twelve month low of $229.72 and a twelve month high of $417.82. The stock has a market capitalization of $13.52 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. The business has a 50 day simple moving average of $335.35 and a 200-day simple moving average of $354.76.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the business posted $4.36 EPS. Equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.